Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael M Lieber

Showing results (71-80 of 81) with videos related to

Pageof 9
Sort By:
Urology|February 8, 2006
Growth factor, cytokine, and vitamin D receptor polymorphisms and risk of benign prostatic hyperplasia in a community-based cohort of menRebecca J Mullan, Eric J Bergstralh, Sara A Farmer, et al.
Diabetes Care|December 12, 2007
Associations between diabetes and clinical markers of benign prostatic hyperplasia among community-dwelling Black and White menAruna V Sarma, James P Burke, Debra J Jacobson, et al.
Urology|June 18, 2003
Comparison of lower urinary tract symptom severity and associated bother between community-dwelling black and white men: the Olmsted County Study of Urinary Symptoms and Health Status and the Flint Men's Health StudyAruna V Sarma, John T Wei, Debra J Jacobson, et al.
The Prostate|September 25, 2004
Polymorphisms in the 5alpha reductase type 2 gene and urologic measures of BPHRosebud O Roberts, Erik J Bergstralh, Sara A Farmer, et al.
The New England Journal of Medicine|June 26, 2003
The influence of finasteride on the development of prostate cancerIan M Thompson, Phyllis J Goodman, Catherine M Tangen, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|July 17, 2014
Factors associated with adherence to an end-of-study biopsy: lessons from the prostate cancer prevention trial (SWOG-Coordinated Intergroup Study S9217)Ellen R Gritz, Kathryn B Arnold, Carol M Moinpour, et al.
The Journal of Urology|April 17, 2002
A comparison of BTA stat, hemoglobin dipstick, telomerase and Vysis UroVysion assays for the detection of urothelial carcinoma in urineKevin C Halling, Walter King, Irina A Sokolova, et al.
JAMA|October 13, 2011
Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT)Eric A Klein, Ian M Thompson, Catherine M Tangen, et al.
The New England Journal of Medicine|December 19, 2003
The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasiaJohn D McConnell, Claus G Roehrborn, Oliver M Bautista, et al.
Journal of the National Cancer Institute|January 20, 2005
Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT)Scott M Lippman, Phyllis J Goodman, Eric A Klein, et al.
Pageof 9

Showing results (71-80 of 81) with videos related to

Sort By:
Pageof 9
Urology|February 8, 2006
Growth factor, cytokine, and vitamin D receptor polymorphisms and risk of benign prostatic hyperplasia in a community-based cohort of menRebecca J Mullan, Eric J Bergstralh, Sara A Farmer, et al.
Diabetes Care|December 12, 2007
Associations between diabetes and clinical markers of benign prostatic hyperplasia among community-dwelling Black and White menAruna V Sarma, James P Burke, Debra J Jacobson, et al.
Urology|June 18, 2003
Comparison of lower urinary tract symptom severity and associated bother between community-dwelling black and white men: the Olmsted County Study of Urinary Symptoms and Health Status and the Flint Men's Health StudyAruna V Sarma, John T Wei, Debra J Jacobson, et al.
The Prostate|September 25, 2004
Polymorphisms in the 5alpha reductase type 2 gene and urologic measures of BPHRosebud O Roberts, Erik J Bergstralh, Sara A Farmer, et al.
The New England Journal of Medicine|June 26, 2003
The influence of finasteride on the development of prostate cancerIan M Thompson, Phyllis J Goodman, Catherine M Tangen, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|July 17, 2014
Factors associated with adherence to an end-of-study biopsy: lessons from the prostate cancer prevention trial (SWOG-Coordinated Intergroup Study S9217)Ellen R Gritz, Kathryn B Arnold, Carol M Moinpour, et al.
The Journal of Urology|April 17, 2002
A comparison of BTA stat, hemoglobin dipstick, telomerase and Vysis UroVysion assays for the detection of urothelial carcinoma in urineKevin C Halling, Walter King, Irina A Sokolova, et al.
JAMA|October 13, 2011
Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT)Eric A Klein, Ian M Thompson, Catherine M Tangen, et al.
The New England Journal of Medicine|December 19, 2003
The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasiaJohn D McConnell, Claus G Roehrborn, Oliver M Bautista, et al.
Journal of the National Cancer Institute|January 20, 2005
Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT)Scott M Lippman, Phyllis J Goodman, Eric A Klein, et al.
Pageof 9